The US Oncology Network | Strategic Alliance Partners

October 27, 2021

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

October 20, 2021

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

October 19, 2021

Ontada, a McKesson business focused on real-world data and evidence, clinical education and provider technology, announced the launch of Health Outcomes Powered by Evidence Studies.

October 12, 2021

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that it has appointed Jason Hammonds as its new president.

July 19, 2021

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

June 29, 2021

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

June 10, 2021

Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.

April 02, 2021

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.

November 11, 2020

Community-based practices in The Network advance value-based care by significantly reducing costs while enhancing care.

May 08, 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the FDA approval of bevacizumab and other novel agents in cervical cancer.

May 05, 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

April 24, 2020

Christopher A. Yasenchak, MD, discusses findings from the phase 2 trial with brentuximab vedotin and nivolumab in patients with newly diagnosed classical Hodgkin lymphoma.

April 07, 2020

The US Oncology Network (The Network) has named prominent cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer.

April 07, 2020

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

February 07, 2020

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.

January 22, 2020

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

December 10, 2019

Top researchers will present abstracts on latest clinical research advancing cancer treatment options.

January 04, 2019

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

October 04, 2018

The US Oncology Network has announced the results of the 2017 Merit-based Incentive Payment System for its affiliated practices.

October 03, 2018

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.